Keryx, Aeterna Zentaris plummet on perifosine colorectal cancer drug failure
This article was originally published in Scrip
Executive Summary
Keryx Biopharmaceuticals tumbled as low as 67% on 2 April after it said that its novel oral anticancer Akt inhibitor, perifosine, plus Xeloda (capecitabine) missed the primary endpoint of improving overall survival versus Xeloda and placebo in the Phase III X-PECT trial to treat refractory advanced colorectal cancer.